Exicure (XCUR) Competitors $10.80 -0.34 (-3.05%) Closing price 04:00 PM EasternExtended Trading$11.18 +0.38 (+3.52%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Exicure (NASDAQ:XCUR) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment. Does the MarketBeat Community prefer XCUR or ATAI? Atai Life Sciences received 325 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 66.53% of users gave Atai Life Sciences an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformExicureOutperform Votes947.37% Underperform Votes1052.63% Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Which has stronger valuation and earnings, XCUR or ATAI? Exicure has higher revenue and earnings than Atai Life Sciences. Exicure is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K136.47-$16.91M-$4.81-2.25Atai Life Sciences$308K947.00-$40.22M-$0.93-1.57 Do insiders & institutionals believe in XCUR or ATAI? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 3.9% of Exicure shares are owned by insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is XCUR or ATAI more profitable? Atai Life Sciences' return on equity of -65.75% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -190.90% -36.75% Atai Life Sciences N/A -65.75%-52.71% Which has more risk & volatility, XCUR or ATAI? Exicure has a beta of 3.74, meaning that its stock price is 274% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Does the media refer more to XCUR or ATAI? In the previous week, Exicure had 2 more articles in the media than Atai Life Sciences. MarketBeat recorded 4 mentions for Exicure and 2 mentions for Atai Life Sciences. Exicure's average media sentiment score of 0.95 beat Atai Life Sciences' score of -0.83 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Do analysts rate XCUR or ATAI? Atai Life Sciences has a consensus target price of $10.50, indicating a potential upside of 619.18%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtai Life Sciences beats Exicure on 10 of the 17 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.23M$6.68B$5.44B$7.81BDividend YieldN/A3.20%5.44%4.30%P/E Ratio-5.227.1422.1418.36Price / Sales136.47238.91389.71101.37Price / CashN/A65.6738.2034.62Price / Book6.176.266.664.18Net Income-$16.91M$142.48M$3.21B$247.71M7 Day Performance27.96%7.91%5.83%6.45%1 Month Performance-18.61%-6.03%-4.31%-3.14%1 Year Performance2,021.81%-0.96%17.83%5.40% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure2.0156 of 5 stars$10.80-3.1%N/A+2,063.1%$68.23M$500,000.00-5.2250Gap UpATAIAtai Life Sciences2.5375 of 5 stars$1.42-3.4%$10.50+639.4%-18.2%$283.69M$308,000.00-1.7580PVLAPalvella Therapeutics3.4797 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AHigh Trading VolumeAURAAura Biosciences2.3075 of 5 stars$5.57+3.9%$22.75+308.4%-22.3%$279.75MN/A-3.2250Positive NewsCYRXCryoport2.4985 of 5 stars$5.52-0.5%$11.67+111.4%-63.7%$275.50M$228.39M-1.631,020Gap DownGLUEMonte Rosa Therapeutics2.9588 of 5 stars$4.46-2.0%$15.50+247.5%-4.6%$274.34M$75.62M-2.4490Positive NewsPHATPhathom Pharmaceuticals3.5849 of 5 stars$3.90-3.2%$21.83+459.8%-54.8%$271.58M$55.25M-0.69110Upcoming EarningsRNACCartesian Therapeutics1.8494 of 5 stars$10.34-1.5%$42.14+307.6%-41.8%$267.88M$38.91M-0.2064TSVT2seventy bio2.2607 of 5 stars$4.99+0.2%$5.60+12.2%+16.9%$261.17M$37.86M-2.68440Upcoming EarningsAnalyst ForecastMNPRMonopar Therapeutics1.0698 of 5 stars$42.71+7.9%$55.33+29.6%+1,256.8%$261.09MN/A-21.6810Gap DownSEPNSepterna2.2295 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ALockup ExpirationPositive News Related Companies and Tools Related Companies Atai Life Sciences Alternatives Palvella Therapeutics Alternatives Aura Biosciences Alternatives Cryoport Alternatives Monte Rosa Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives 2seventy bio Alternatives Monopar Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
